Cancer Metastasic Melanoma
The years 2011–16 represent a watershed era in melanoma history. This period has seen the approval of several molecularly targeted or immunotherapy drugs that meaningfully improve outcomes for patients with unresectable or metastatic melanoma. Targeting the MAP kinase (MAPK) pathway through combined BRAF and MEK inhibition has been very successful, yet the eventual development of resistance through reactivation of MAPK signalling is nearly inevitable. Paolo Ascierto and colleagues report the extended follow-up results of the coBRIM phase 3 trial evaluating the addition of the MEK inhibitor cobimetinib to the BRAF inhibitor vemurafenib in patients with previously untreated BRAF-mutant metastatic melanoma.